BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
BioNexus Gene Lab's pe ratio was 670.6× on Aug 31, 2020.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Aug 31, 2020 | 670.6× | – |
See a number that looks wrong?